{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:46:15Z","timestamp":1775688375830,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,21]],"date-time":"2013-07-21T00:00:00Z","timestamp":1374364800000},"content-version":"vor","delay-in-days":2577,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.curtheres.2006.08.003","type":"journal-article","created":{"date-parts":[[2006,10,10]],"date-time":"2006-10-10T11:24:57Z","timestamp":1160479497000},"page":"258-269","source":"Crossref","is-referenced-by-count":11,"title":["Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study"],"prefix":"10.1016","volume":"67","author":[{"given":"Xiao-Cong","family":"Zuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Kun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-hong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-De","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2006.08.003_bib1","unstructured":"Abilify (aripiprazole tablets) [prescribing information]. New York, NY: Bristol-Myers Squibb Company; 2004; and Rockville, Md: Otsuka America Pharmaceutical, Inc; 2004. Available at: http:\/\/www.abilify.com. Accessed April 15, 2004."},{"key":"10.1016\/j.curtheres.2006.08.003_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a highaffinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharrnacol Exp Ther"},{"key":"10.1016\/j.curtheres.2006.08.003_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2006.08.003_bib4","first-page":"S176","article-title":"Aripiprazole: A dopamine-serotonin system stabilizer","volume":"5","author":"McQuade","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.curtheres.2006.08.003_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s007020200033","article-title":"Partial dopamine agonists in the treatment of psychosis","volume":"109","author":"Tamminga","year":"2002","journal-title":"J Neural Transm"},{"key":"10.1016\/j.curtheres.2006.08.003_bib6","article-title":"Task Force for the Handbook of Psychiatric Measures","author":"Rush","year":"2000"},{"key":"10.1016\/j.curtheres.2006.08.003_bib7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.curtheres.2006.08.003_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.curtheres.2006.08.003_bib9","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.curtheres.2006.08.003_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int J Neuropsychopharmacol."},{"key":"10.1016\/j.curtheres.2006.08.003_bib11","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0090-9556(24)15029-5","article-title":"Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6","volume":"27","author":"Shin","year":"1999","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.curtheres.2006.08.003_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0091270003261901","article-title":"Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers","volume":"44","author":"Mallikaarjun","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 3","key":"10.1016\/j.curtheres.2006.08.003_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0924-977X(02)80406-0","article-title":"Safety and tolerability of aripiprazole at doses higher than 30 mg","volume":"12","author":"Auby","year":"2002","journal-title":"Eur Neuropsychopharmacol."},{"key":"10.1016\/j.curtheres.2006.08.003_bib14","series-title":"International Conference on Harmonisation-World Health Organization","author":"European Agency for the Evaluation of Medicinal Products","year":"2002"},{"key":"10.1016\/j.curtheres.2006.08.003_bib15","series-title":"Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects [WMA Web site]","author":"World Medical Association Declaration of Helsinki","year":"1989"},{"key":"10.1016\/j.curtheres.2006.08.003_bib16","first-page":"157","article-title":"Body weight of Chinese adults by sex, age and body height and criterion of obesity based on body mass index","volume":"17","author":"Huang","year":"1992","journal-title":"Nutr Sci J."},{"key":"10.1016\/j.curtheres.2006.08.003_bib17","series-title":"Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-1V-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.curtheres.2006.08.003_bib18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jchromb.2005.06.023","article-title":"Development and validation of an LC-MS\/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma","volume":"822","author":"Kubo","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"10.1016\/j.curtheres.2006.08.003_bib19","first-page":"23","article-title":"Diagnostics of Clinical Experiment","author":"Hanmin","year":"2004"},{"key":"10.1016\/j.curtheres.2006.08.003_bib20","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Swainston Harrison","year":"2004","journal-title":"Drugs"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X06000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X06000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T09:54:16Z","timestamp":1736589256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X06000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0011393X06000592"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2006.08.003","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}